Does the usage of cyclopentolate, phenylephrine, and tropicamide compare with cyclopentolate and phenylephrine give more ocular and systemic effects in children with refractive error?

Research Unit of Cicendo National Eye Hospital0 个研究点目标入组 54 人开始时间: 2022年10月25日最近更新: 2022年11月7日

适应症

试验速览

暂无简介。

•Children 6-18 years of age who had mild to moderate refractive errors before administration of cycloplegic agents (myopia <6.00 D, hyperopia <3.00 D, and astigmatism <3.00 D)

•1. Visual disturbances unrelated to refractive errors, such as corneal opacities, uveitis, glaucoma, cataracts, posterior segment disorders, and disorders of the optic nerve/visual pathway
•2. History of ocular surgery
•3. Pupillary abnormalities or other neurological disorders
•4. History of cardiovascular disease
•5. Receiving systemic or ocular medical therapy that affects pupil function and/or accommodation
•6. High anisometropia (difference in eye refractive status =2.00 D)
•7. Strabismus, amblyopia
•8. Light colored iris (green or blue iris)
•9. Albinism
•10. History of allergy to the components of the research drug
•11. Children who were not cooperative during drug administration, did not complete autorefractometer and pupil diameter measurements, or developed adverse drug reactions after administration of the regimen

发起方

Research Unit of Cicendo National Eye Hospital